Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vistakon
ClinicalTrials.gov Identifier:
NCT01669629
First received: August 16, 2012
Last updated: October 28, 2014
Last verified: October 2014

August 16, 2012
October 28, 2014
August 2012
November 2012   (final data collection date for primary outcome measure)
Subject Reported Ease of Removal [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant. Outcome is reported as aggregate number of subjects who reported Excellent/Very Good at their 1-week visit.
Subject Reported Ease of Removal [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant using a non-inferiority odds-ratio margin.
Complete list of historical versions of study NCT01669629 on ClinicalTrials.gov Archive Site
  • Subject Reported Overall Comfort [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant. Summary is reported as an aggregate of Excellent/Very Good at their 1-week visit.
  • Subject Reported Overall Vision [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant using an aggregate summary of excellent/very good at their 1-week visit.
  • Binocular Snellen Visual Acuity [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Snellen visual acuity percentage of eyes with a visual acuity of eyesight testing at a 20/20 level or better by eye.
  • Overall Corneal Staining [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]

    Proportion of subjects that have corneal staining on the 0-4 the NEI/Industry Workshop guidelines scale, measured by eye.

    Grade 1 or higher is reported as a percentage of total eyes.

  • Subject Reported Overall Comfort [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant using a non-inferiority odds-ratio margin.
  • Subject Reported Overall Vision [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Measured on a 5 point-scale of excellence (excellent, very good, good, fair and poor) per a participant using a non-inferiority odds-ratio margin.
  • Binocular Snellen Visual Acuity [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Snellen visual acuity percentage of eyes with a visual acuity of 20/20-2 or better by eye.
  • Overall corneal staining [ Time Frame: 6-10 Days ] [ Designated as safety issue: No ]
    Proportion of subjects that have corneal staining on the 0-4 NEI scale measured by eye.
Not Provided
Not Provided
 
Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear
Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear

This is a one week 2x2 crossover study comparing delefilcon A with etafilcon A, with a primary hypothesis of comparing the handling of each lens. Additional secondary markers are measured looking at subjective comfort and vision of the lenses.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Myopia
  • Device: delefilcon A
    Daily wear soft contact lens for bilateral distance vision correction use.
  • Device: etafilcon A
    Daily wear soft contact lens for bilateral distance vision correction use.
  • Experimental: Delefilcon A/ Etafilcon A
    6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
    Interventions:
    • Device: delefilcon A
    • Device: etafilcon A
  • Experimental: Etafilcon A / Delefilcon A
    6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
    Interventions:
    • Device: delefilcon A
    • Device: etafilcon A
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
183
November 2012
November 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject must be between 18 and 45 years of age (inclusive) with no presbyopic add.
  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. This should be recorded on the Case Report Form (CRF).
  • The subject must be willing to wear the study lenses for at least 8 hours per day, 7 days per week.
  • The subject must be a current successful soft contact lens wearer in both eyes
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • The subject's subjective refraction must result in a vertex corrected spherical contact lens prescription in the range of -1.00D to -6.00D in each eye.
  • The subject's refractive astigmatism must be less than or equal to 0.75D in both eyes.
  • The subject must have best corrected visual acuity of 20/30 (6/9) or better in each eye.
  • The subject must require a visual correction in both eyes (no monofit or monovision allowed).
  • The subject must have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:

    1. No amblyopia.
    2. No evidence of lid abnormality or infection (including blepharitis/meibomitis).
    3. No conjunctival abnormality or infection.
    4. No clinically significant slit lamp findings (i.e. stromal edema, vascularization, infiltrates or abnormal opacities).
    5. No other active ocular disease.

Exclusion Criteria:

  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
  • Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
  • Clinically significant (Grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Pregnancy or lactation.
  • No extended wear in the last 3 months.
  • Diabetes.
  • Infectious diseases (e.g. hepatitis, tuberculosis) or an immunosuppressive disease (e.g. HIV).
  • Employee or family member of the staff of the investigational site.
Both
18 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01669629
CR-005199
No
Vistakon
Vistakon
Not Provided
Not Provided
Vistakon
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP